(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 16 E- mail: mail@ emea. eu. int http: // www. emea. eu. int ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Jaký přínos přípravku NeuroBloc byl prokázán v průběhu studií?
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea.eu.int http://www.emea.eu.int ©EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged zervikaler Dystonie angewendet werden kann) ansprachen, während die vierte Studie nur solche Patienten untersuchte, die auf Botulinumtoxin Typ A ansprachen.